Introduction to ALK inhibitors

(6:17)

How do ALK-inhibitors work in ALK-positive lung cancer?

(2:50)

Choosing the best ALK inhibitor for lung cancer

(1:24)

ALK Inhibitor Sequencing in NSCLC

(6:27)

Next-generation ALK inhibitors: treatment sequencing and resistance

(1:42)

First and Second Generation ALK Inhibitors for the Treatment of Lung Cancer

(22:10)

Case Study: Progression on ALK Inhibitors in NSCLC

(6:4)

Dr. Corey Langer discusses ALK inhibitors

(2:18)

How Do the New ALK Inhibitor Drugs Compare to Xalkori (Crizotinib) for ALK+ Lung Cancer Patients?

(4:58)

Efficacy of Next-Generation ALK Inhibitors in NSCLC

(4:23)

Third-Generation ALK Inhibitors for NSCLC

(8:17)

New ALK Inhibitor Drugs vs Xalkori (Crizotinib) for ALK+ Lung Cancer Patients

(2:15)

ALK Inhibitors for Acquired Resistance: Zykadia and Alectinib

(3:44)

Should a Second Generation ALK Inhibitor be First Line Therapy for Patients with ALK-Positive NSCLC?

(4:14)

ALK Positive Lung Cancer in 2023 and Beyond: Thinking Outside the Box with Dr. Alice Shaw

(42:31)

Are There Clinically Significant Differences Among the Second Generation ALK Inhibitors?

(4:44)

Timing of Second Generation ALK Inhibitors: First Line vs. Treatment after Acquired Resistance

(2:20)

Can or Will Specific Molecular Characteristics Help Determine Which ALK Inhibitor to Choose?

(4:14)

Molecularly-guided treatment of advanced NSCLC: ALK inhibitor sequencing

(2:10)